百濟神州(06160.HK)自主研發藥品於俄羅斯取得首次藥政批準
百濟神州(06160.HK)公佈,自主研發的布魯頓氏酪氨酸激(酉每)小分子抑制劑「百悅澤(澤布替尼)」在俄羅斯獲批用於治療復發或難治性套細胞淋巴瘤患者,爲百悅澤於俄羅斯取得的首次藥政批準。基於獨家分銷協議,Nanolek將在俄羅斯負責百悅澤的商業化。
公司表示,目前百悅澤已在10個國家獲批用於治療套細胞淋巴瘤,包括美國、中國、加拿大、澳大利亞和其它國家。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.